Kura Oncology KURA Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -443.5%-70.4pp | -449.9%-91.4pp | -377%— | -390%— | -373.2%— | |
| Net margin | -411.2%-77.6pp | -412.9%-90.1pp | -340.9%— | -350%— | -333.6%— | |
| EBITDA margin | -441.9%-70.4pp | -448.4%-91.4pp | -375.7%— | -388.4%— | -371.6%— | |
| Returns | ||||||
| Return on equity | -124.7%-82.9pp | -94.8%-51.9pp | -65.1%-18.8pp | -51.1%-11.8pp | -41.8%-4.5pp | |
| Return on assets | -42.2%-14.2pp | -37.2%-8.4pp | -38.4%+3.0pp | -32.9%+3.1pp | -28%+6.3pp | |
| Return on invested capital | -149.3%-99.3pp | -241.7%-175pp | -86%-33.6pp | -64.6%-19.6pp | -50%-8.6pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×— | 0.1×— | |
| Liquidity | ||||||
| Current ratio | 6.1×-1.9× | 6.1×-3.4× | 5.1×-6.4× | 6.2×-8.8× | 8.1×-8.6× | |
| Quick ratio | 6.1×-1.9× | 6.1×-3.4× | 5.1×-6.4× | 6.2×-8.8× | 8.1×-8.6× | |
| Cash ratio | 0.4×-0.2× | 1.3×-1.6× | 0.8×-0.4× | 0.8×-0.6× | 0.6×-0.7× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×+0.2× | 0.1×+0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Interest coverage | -216.7×-89.8× | -200.8×-81.5× | -152.8×-21.1× | -138.4×-17.4× | -126.9×-14.0× | |
| Per Share | ||||||
| Book value per share | $1.22-70.8% | $1.99-58.6% | $2.77-43.2% | $3.49-35.2% | $4.17-30.7% | |
| Valuation | ||||||
| Market capitalization | $919.7M+81.6% | $904.11M+33.5% | $768.16M-54.6% | $517.72M-70.0% | $532.98M-70.2% | |
| Enterprise value | $904.89M+90.7% | $775.47M+65.2% | $692.33M-58.3% | $455.24M-73.2% | $501.07M-71.6% | |
| Price / sales | 12.8×+3.5× | 13.4×+0.8× | 12.1×— | 9.2×— | 9.8×— | |
| Price / book | 8.5×+7.1× | 5.2×+3.6× | 3.2×-0.8× | 1.7×-2.0× | 1.5×-2.1× | |
| EV / sales | 12.6×+3.9× | 11.5×+2.8× | 10.9×— | 8.1×— | 9.2×— | |
| Earnings yield | -32%+3.9pp | -30.8%-5.1pp | -28.2%-16.6pp | -38.1%-27.6pp | -34.1%-24.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Kura Oncology's ratios come from?
- Every ratio is computed from Kura Oncology's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
